Rethinking screening for thyroid autoimmunity in vitiligo

See related letters on pages e231 and e233

http://ift.tt/2eSY3kk

Reply to: “Comment on ‘Review of patient registries in dermatology’”

To the Editor: We thank Zweegers et al for suggesting additional helpful, important registries. The psoriasis registries they described provide important complements to randomized control trial (RCT) data. Registries provide information about real-world effectiveness, about how well drugs work over the course of long-term, chronic diseases, and perhaps most importantly, about drug safety, as clinical trials tend not to be large enough or long enough to fully elucidate rare risks. A limitation of patient registries is that patients are generally not randomized to different treatment groups, making it essential to address potential biases in treatment assignment when making comparisons between different treatment groups.

http://ift.tt/2fN8yYt

A chronic poorly healing wound on the right lateral trunk

An 82-year-old man with a history of hypertension and coronary artery disease presented with a 6-month history of a chronic poor healing wound. He had undergone coronary artery intervention three times within the past 2 years, with development of painful erythema on the right lateral trunk immediately after the third procedure. In the following months, ulcers developed within and showed no tendency to heal. The physical examination revealed a 7 cm × 8 cm hyperpigmented indurated patch with overlying ulcers and telangiectasia on the right lateral trunk (Fig 1).

http://ift.tt/2g7u3XN

Appearance of lentigines in psoriasis patients treated with apremilast

To the Editor: The development of lentigines in areas previously affected by psoriasis plaques is a rare event mainly reported after phototherapy. Several cases of lentigines appearing in resolving psoriatic plaques during or after treatment with anti-tumor necrosis factor (TNF) or anti-interleukin (IL)-12/IL-23 drugs have been reported but they remain anecdotal.1-3 Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that was approved by the US Food and Drug Administration (FDA) in 2014 and by the European Medical Agency in 2015 for the treatment of psoriasis and psoriatic arthritis.

http://ift.tt/2fN8uId

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Conditions:   Attenuated Familial Adenomatous Polyposis;   Familial Adenomatous Polyposis
Interventions:   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified November 2016

http://ift.tt/2f8LOkB

Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Conditions:   Esophageal Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Biological: durvalumab;   Drug: carboplatin AUC 2/paclitaxel;   Radiation: External beam radiation;   Procedure: esophagogastrectomy
Sponsors:   Memorial Sloan Kettering Cancer Center;   AstraZeneca
Recruiting - verified November 2016

http://ift.tt/2extqWn

Exercise Prior to Oesophagectomy

Conditions:   Postoperative Complications (Cardiopulmonary);   Oesophageal Adenocarcinoma
Interventions:   Behavioral: Pre-operative Exercise Programme (my-PEP);   Behavioral: Home Exercise Programme (HEP)
Sponsor:   University of East Anglia
Recruiting - verified November 2016

http://ift.tt/2f8KbDB